First AD

Second AD

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss considering factors for immunotherapy agents in advanced biliary tract cancer.

Choosing Among IO Agents in Advanced BTC

Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Updates in Treatment Strategies for Advanced Biliary Tract Cancer

OncLive News Network®

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss considering factors for immunotherapy agents in advanced biliary tract cancer.


Considering Factors When Choosing Among IO Agents in Advanced BTC

Prognosis and Standards of Care in Advanced Biliary Tract Cancer

Discussion of a Patient Case of Advanced BTC

Homing in on the TOPAZ-1 Trial in Biliary Tract Cancer

Putting TOPAZ-1 Data into Context for Patients With Advanced BTC

Clinical Implications of 3-Year OS Data With Durvalumab/Chemo in Advanced BTC

Factoring in Trastuzumab Deruxtecan in the Advanced BTC Setting

The Investigational Pipeline for Advanced BTC